Axsome Therapeutics (NASDAQ:AXSM) CEO Herriot Tabuteau Sells 49,252 Shares of Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CEO Herriot Tabuteau sold 49,252 shares of the business’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $144.59, for a total value of $7,121,346.68. Following the sale, the chief executive officer owned 7,229 shares of the company’s stock, valued at approximately $1,045,241.11. The trade was a 87.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Herriot Tabuteau also recently made the following trade(s):

• On Thursday, December 4th, Herriot Tabuteau sold 10,558 shares of Axsome Therapeutics stock. The stock was sold at an average price of $148.18, for a total value of $1,564,484.44.
• On Wednesday, December 3rd, Herriot Tabuteau sold 20,163 shares of Axsome Therapeutics stock. The shares were sold at an average price of $146.94, for a total transaction of $2,962,751.22.
• On Tuesday, November 4th, Herriot Tabuteau sold 50,459 shares of Axsome Therapeutics stock. The shares were sold at an average price of $133.79, for a total transaction of $6,750,909.61.
• On Wednesday, November 5th, Herriot Tabuteau sold 21,775 shares of Axsome Therapeutics stock. The shares were sold at an average price of $134.49, for a total transaction of $2,928,519.75.
• On Monday, November 3rd, Herriot Tabuteau sold 91,705 shares of Axsome Therapeutics stock. The shares were sold at an average price of $132.34, for a total transaction of $12,136,239.70.
• On Tuesday, October 7th, Herriot Tabuteau sold 13,390 shares of Axsome Therapeutics stock. The stock was sold at an average price of $118.77, for a total value of $1,590,330.30.
• On Wednesday, October 8th, Herriot Tabuteau sold 12,774 shares of Axsome Therapeutics stock. The stock was sold at an average price of $118.84, for a total value of $1,518,062.16.
• On Monday, October 6th, Herriot Tabuteau sold 19,220 shares of Axsome Therapeutics stock. The shares were sold at an average price of $120.17, for a total value of $2,309,667.40.
• On Tuesday, September 16th, Herriot Tabuteau sold 19,719 shares of Axsome Therapeutics stock. The stock was sold at an average price of $114.19, for a total value of $2,251,712.61.
• On Friday, September 12th, Herriot Tabuteau sold 27,907 shares of Axsome Therapeutics stock. The stock was sold at an average price of $118.96, for a total transaction of $3,319,816.72.

Axsome Therapeutics Trading Up 0.2%

Shares of NASDAQ AXSM traded up $0.23 during midday trading on Thursday, reaching $148.04. 358,671 shares of the stock were exchanged, compared to its average volume of 538,108. Axsome Therapeutics, Inc. has a 12 month low of $75.56 and a 12 month high of $152.94. The company has a market capitalization of $7.46 billion, a price-to-earnings ratio of -31.70 and a beta of 0.48. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.50. The business has a 50-day simple moving average of $134.32 and a two-hundred day simple moving average of $118.51.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.12). The business had revenue of $170.99 million for the quarter, compared to the consensus estimate of $162.96 million. Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The company’s revenue was up 63.2% compared to the same quarter last year. As a group, equities research analysts expect that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Hedge Funds Weigh In On Axsome Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd acquired a new position in shares of Axsome Therapeutics in the 1st quarter valued at approximately $25,000. Versant Capital Management Inc increased its stake in Axsome Therapeutics by 20,300.0% in the third quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock valued at $25,000 after acquiring an additional 203 shares during the last quarter. Quantbot Technologies LP acquired a new position in Axsome Therapeutics during the first quarter valued at approximately $31,000. First Horizon Corp bought a new stake in Axsome Therapeutics during the third quarter worth $34,000. Finally, Optiver Holding B.V. boosted its holdings in shares of Axsome Therapeutics by 82.3% in the 3rd quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock valued at $35,000 after purchasing an additional 130 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently commented on AXSM shares. Royal Bank Of Canada boosted their price objective on shares of Axsome Therapeutics from $189.00 to $198.00 and gave the company an “outperform” rating in a research report on Tuesday, November 4th. Needham & Company LLC reissued a “buy” rating and issued a $154.00 target price on shares of Axsome Therapeutics in a research report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Wednesday, October 8th. Wells Fargo & Company lowered their price objective on shares of Axsome Therapeutics from $163.00 to $157.00 and set an “overweight” rating on the stock in a report on Tuesday, November 4th. Finally, HC Wainwright raised their target price on shares of Axsome Therapeutics from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $179.88.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.